The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Imaging synaptic density in the living human brain
Abstract
Synaptic density in the living human brain was measured with positron emission tomography and a synaptic vesicle glycoprotein 2A tracer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo imaging of synaptic density is now possible using PET and [ 11 C]UCB-J - a radioligand that binds to the synaptic vesicle protein 2A (SV2A) 41 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [41]
In the citing paper
“the most common method to quantify synaptic density has been the quantification of pre-(e.g., synaptophysin [9], synapsin [8]) and post-synaptic (e.g., PSD-95 [10]) genes/proteins”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
In the citing paper
“there was also good correlation between SV2A and the “gold standard” pre-synaptic density marker synaptophysin in western blot and confocal microscopy experiments”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“Thus, it was decided that SV2A can be used as an alternative to synaptophysin for quantification of synapse density”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“quantification of radiotracer binding to SV2A does correlate with measures of synaptic vesicle number [8,9,69,70] and expression of other pre-synaptic proteins classically used in postmortem and in vitro work (e.g., synaptophysin, synapsin).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373 · cited 2×
“2 × 10(14) synapses per liter of brain tissue, as reported for the female human brain (42), and two to five SV2A copies per vesicle (31, 36), it can be estimated that there are 154 to 385 vesicles per synapse.”
BackgroundAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · cited 1×
“Moreover, regional synaptic changes have been demonstrated in patients with autism (10), depression (11), or schizophrenia (12, 13).”
BackgroundWiedenmann, B., & Franke, W. W. (1985) · Cell · doi:10.1016/s0092-8674(85)80082-9 · Cited by 1,428 · cited 1×
“SYN is themost abundant synaptic vesicle protein (31) and is a widely used marker of synaptic density (32, 33), because it was one of the first characterized (29, 34) and cloned (35) vesicle membrane proteins.”
BackgroundLoss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146
Research works printed but not linked: 1
- 10.1097/01.wcb.0000033967.83623.34 · doi:10.1097/01.wcb.0000033967.83623.34 · Paper page
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
“176,177 A future direction for the field could be to identifymorespecificrolesthatvarioussynapticbiomarkerscouldplay and possibly to break out synaptic biomarkers from the broader N category.”
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00013-3 · Cited by 783
Protein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675
“now being developed in humans, and could be reversetranslated for use in rodent studies [127].”
BackgroundCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Lower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Self-citationChen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431
Self-citationRadiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
Crișan, G., Moldovean-Cioroianu, N. S., Timaru, D.-G., Andrieș, G., Căinap, C., & Chiș, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095023 · Cited by 337
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
“It would be interesting to use novel PET tracers of synaptic density (Finnema et al., 2016) in combination with LC imaging to assess how differences in LC synapse density relate to LC MRI contrast in neurodegenerative diseases.”
BackgroundThe clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
History and future technical innovation in positron emission tomography
Jones, T., & Townsend, D. (2017) · Journal of Medical Imaging · doi:10.1117/1.jmi.4.1.011013 · Cited by 303
“Another exciting recent development has been that of a PET biomarker for imaging the synapse, which raises the possibility to combine imaging of the brain and the periphery.(109) Since whole-body scanners now cover up to 25 cm axially, the entire human brain can be imaged in a single bed position, obviating the need f…”
BackgroundA Synergistic Core for Human Brain Evolution and Cognition
Luppi, A. I., Mediano, P. A. M., Rosas, F. E., Holland, N., Fryer, T. D., O’Brien, J. T., Rowe, J. B., Menon, D. K., Bor, D., & Stamatakis, E. A. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01070-0 · Cited by 314
Commonalities in epileptogenic processes from different acute brain insults: Do they translate?
Klein, P., Dingledine, R., Aronica, E., Bernard, C., Blümcke, I., Boison, D., Brodie, M. J., Brooks‐Kayal, A. R., Engel, J., Forcelli, P. A., et al. (2018) · Epilepsia · doi:10.1111/epi.13965 · Cited by 284
“A newly developed synaptic density marker appears promising to measure neurodegeneration and neuronal network changes during epileptogenesis.(299) Other indirect target engagement measures could include quantitative EEG or magnetoencephalographic techniques(300) or assessment of specific molecular biomarkers in plasma…”
Backgroundvan Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
“18F-UCBJ is a PET radiotracer considered to be sensitive for synaptic loss, because altered uptake of 18F-UCB-J in the gray matter was correlated to altered expression of SV2A and lower synaptic density [219,220].”
BackgroundIn vivo measurement of widespread synaptic loss in Alzheimer’s disease with SV2A PET
Mecca, A. P., Chen, M., O'Dell, R. S., Naganawa, M., Toyonaga, T., Godek, T. A., Harris, J. E., Bartlett, H. H., Zhao, W., Nabulsi, N. B., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12097 · Cited by 288
Self-citationThe synapse in traumatic brain injury
Jamjoom, A. A. B., Rhodes, J., Andrews, P. J. D., & Grant, S. G. N. (2021) · Brain · doi:10.1093/brain/awaa321 · Cited by 241
Molecular biomarkers of Alzheimer's disease: progress and prospects
Lashley, T., Schott, J. M., Weston, P., Murray, C. E., Wellington, H., Keshavan, A., Foti, S. C., Foiani, M., Toombs, J., Rohrer, J. D., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031781 · Cited by 230
“synaptic density in the living human brain (Finnema et al., 2016).”
The synaptic hypothesis of schizophrenia version III: a master mechanism
Howes, O. D., & Onwordi, E. C. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02043-w · Cited by 234
“As a marker of SV2A levels, changes in [ 11 C]UCB-J binding could re fl ect altered SV2A levels, and/or synaptic vesicle numbers and/or pre-synaptic terminal density and/or synaptic density.”
BackgroundMethodInfluentialImaging biomarkers in neurodegeneration: current and future practices
Young, P. N. E., Estarellas, M., Coomans, E., Srikrishna, M., Beaumont, H., Maass, A., Venkataraman, A. V., Lissaman, R., Jiménez, D., Betts, M. J., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00612-7 · Cited by 225
“Recently, these changes have been able to be visualised directly in vivo in humans [84].”
BackgroundOnwordi, E. C., Halff, E. F., Whitehurst, T., Mansur, A., Cotel, M.-C., Wells, L., Creeney, H., Bonsall, D., Rogdaki, M., Shatalina, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14122-0 · Cited by 243
Synaptic plasticity and mental health: methods, challenges and opportunities
Appelbaum, L. G., Shenasa, M. A., Stolz, L., & Daskalakis, Z. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01370-w · Cited by 240
“Furthermore, quantifying age-related synaptic density changes over time is also a key step in moving forward to have well-delineated controls [35].”
BackgroundExpansion and Renormalization of Human Brain Structure During Skill Acquisition
Wenger, E., Brozzoli, C., Lindenberger, U., & Lövdén, M. (2017) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2017.09.008 · Cited by 206
“Recently, a new radioligand has been used in positron emission tomography (PET) to quantify synaptic density in the living brain [84], which opens insights into cellular processes.”
Finnema, S. J., Nabulsi, N. B., Mercier, J., Lin, S.-F., Chen, M.-K., Matuskey, D., Gallezot, J.-D., Henry, S., Hannestad, J., Huang, Y., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17724947 · Cited by 218
Self-citationTargeting the Synapse in Alzheimer’s Disease
Jackson, J., Jambrina, E., Li, J., Marston, H., Menzies, F., Phillips, K., & Gilmour, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00735 · Cited by 215
“The most advanced work here focuses on the presynaptic vesicle protein SV2a, and initial work suggests ligands like UCB-J show promise for the ability to measure synapse density over time (Finnema et al., 2016).”
BackgroundRaval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020835 · Cited by 200
Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2020) · doi:10.20944/preprints202011.0742.v1 · Cited by 200
Cerebral dysfunctions caused by sepsis during ageing
Manabe, T., & Heneka, M. T. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00643-7 · Cited by 191
Mecca, A. P., O'Dell, R. S., Sharp, E. S., Banks, E. R., Bartlett, H. H., Zhao, W., Lipior, S., Diepenbrock, N. G., Chen, M., Naganawa, M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12582 · Cited by 186
Self-citationSynaptic Changes in Parkinson Disease Assessed with in vivo Imaging
Matuskey, D., Tinaz, S., Wilcox, K. C., Naganawa, M., Toyonaga, T., Dias, M., Henry, S., Pittman, B., Ropchan, J., Nabulsi, N., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25682 · Cited by 180
“We have recently developed a noninvasive in vivo imaging technique using [(11)C]UCB-J positron emission tomography (PET) to measure the density of synapses in humans with SV2A, an essential vesicle membrane protein present in virtually all presynaptic terminals.(12,13) As SV2A has a relatively consistent copy number p…”
MethodResultSelf-citationSynaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
Targeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 190
“PET imaging of SV2A was able detect significant synapse loss in patients with temporal lobe epilepsy 273 , schizophrenia 274,275 and depression 276 .”
Deregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria
Gowda, P., Reddy, P. H., & Kumar, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101529 · Cited by 163
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165
Biomarkers for Alzheimer’s Disease Early Diagnosis
Ausó, E., Gómez‐Vicente, V., & Esquiva, G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030114 · Cited by 169
“Regarding neuronal connectivity dysfunction, a novel PET tracer that binds to synaptic vesicle glycoprotein 2A (SV2A) can be used to quantify synaptic density in vivo, predicting the stage of AD [29].”
BackgroundThe role of neuroimaging in Parkinson’s disease
Bidesi, N., Andersen, I. V., Windhorst, A., Shalgunov, V., & Herth, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15516 · Cited by 122
“SV2A can be imaged with the PET tracer [11C]UCB- J (Finnema et al., 2016).”
BackgroundDifferential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease
Groot, C., van Loenhoud, A. C., Barkhof, F., van Berckel, B. N. M., Koene, T., Teunissen, C. E., Scheltens, P., van der Flier, W. M., & Ossenkoppele, R. (2017) · Neurology · doi:10.1212/wnl.0000000000004802 · Cited by 158
van Berlekom, A. B., Muflihah, C. H., Snijders, G. J. L., MacGillavry, H. D., Middeldorp, J., Hol, E. M., Kahn, R. S., & de Witte, L. D. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz060 · Cited by 187
Research Progress in the Pathogenesis of Alzheimer's Disease
Chen, Y. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.235112 · Cited by 153
Naganawa, M., Li, S., Nabulsi, N., Henry, S., Zheng, M.-Q., Pracitto, R., Cai, Z., Gao, H., Kapinos, M., Labaree, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.249144 · Cited by 138
“The CS has been proposed as a suitable reference region because of its negligible SV2A level in the baboon brain, as observed by Western blot analysis (4).”
MethodSelf-citationInformation decomposition and the informational architecture of the brain
Luppi, A. I., Rosas, F. E., Mediano, P. A. M., Menon, D. K., & Stamatakis, E. A. (2024) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2023.11.005 · Cited by 140
“In vivo PET imaging [63] and data-driven transcriptomic analysis [64] Redundancy Connectome human brain delineates a unimodal – transmodal synergy – redundancy axis.”
PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
“and that brain regional SV2A levels closely correlated with those of synaptophysin, another commonly used marker for synaptic density [29].”
BackgroundMethodInfluentialSelf-citationLocal molecular and global connectomic contributions to cross-disorder cortical abnormalities
Hansen, J. Y., Shafiei, G., Vogel, J. W., Smart, K. A., Bearden, C. E., Hoogman, M., Franke, B., van Rooij, D., Buitelaar, J. K., McDonald, C. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32420-y · Cited by 140
Self-citationChou, Y., Sundman, M., That, V. T., Green, J., & Trapani, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101660 · Cited by 142
Assessment of a white matter reference region for 11 C-UCB-J PET quantification
Rossano, S., Toyonaga, T., Finnema, S. J., Naganawa, M., Lu, Y., Nabulsi, N., Ropchan, J., De Bruyn, S., Otoul, C., Stockis, A., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19879230 · Cited by 126
“However, as reported in the first-in-human study, during displacement scans using SV2A specific drug levetiracetam (LEV), (11)C-UCB-J concentration decreased by about 10–15% in the CS, indicating the presence of some degree of specific binding in that region.(7) In this work, we further carefully characterize (11)C-UC…”
BackgroundMethodSelf-citationLi, S., Cai, Z., Wu, X., Holden, D., Pracitto, R., Kapinos, M., Gao, H., Labaree, D. C., Nabulsi, N., Carson, R. E., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00526 · Cited by 130
Self-citationMcCluskey, S. P., Plisson, C., Rabiner, E. A., & Howes, O. D. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04488-0 · Cited by 135
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
Koole, M., van Aalst, J., Devrome, M., Mertens, N., Serdons, K., Lacroix, B., Mercier, J., Sciberras, D., Maguire, P., & Van Laere, K. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4119-8 · Cited by 118
Self-citationO’Dell, R. S., Mecca, A. P., Chen, M.-K., Naganawa, M., Toyonaga, T., Lu, Y., Godek, T. A., Harris, J. E., Bartlett, H. H., Banks, E. R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00742-y · Cited by 111
Self-citationIn vivo tau pathology is associated with synaptic loss and altered synaptic function
Coomans, E. M., Schoonhoven, D. N., Tuncel, H., Verfaillie, S. C. J., Wolters, E. E., Boellaard, R., Ossenkoppele, R., den Braber, A., Scheper, W., Schober, P. R., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00772-0 · Cited by 108
“Recent studies in patients with AD have observed strongest reductions in SV2A radiotracer-binding in the hippocampus [17–19], a key region for structural synaptic degeneration in AD [20].”
BackgroundMethodInfluentialImaging of Synaptic Density in Neurodegenerative Disorders
Carson, R. E., Naganawa, M., Toyonaga, T., Koohsari, S., Yang, Y., Chen, M.-K., Matuskey, D., & Finnema, S. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263201 · Cited by 104
“Subsequent SV2A human imaging data were highly consistent with preclinical data; that is, (11)C-UCB-J has ideal imaging characteristics (24), with (11)C-UCB-A possessing slow binding kinetics (25) and (18)F-UCB-H having low specific binding in the brain (26).”
BackgroundResultSelf-citationPET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research
Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102
Self-citationVenkataraman, A. V., Mansur, A., Rizzo, G., Bishop, C., Lewis, Y., Kocagoncu, E., Lingford-Hughes, A., Huiban, M., Passchier, J., Rowe, J. B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abk1051 · Cited by 101
“A centrum semiovale (CS) ROI was also generated from the automated anatomic labeling template as defined previously for use as a nonspecific reference region for [11C]UCB-J (47).”
MethodIn vivo evidence of lower synaptic vesicle density in schizophrenia
Radhakrishnan, R., Skosnik, P. D., Ranganathan, M., Naganawa, M., Toyonaga, T., Finnema, S., Hillmer, A. T., Esterlis, I., Huang, Y., Nabulsi, N., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01184-0 · Cited by 100
Self-citationA review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease
Delva, A., Weehaeghe, D. V., Koole, M. J. B., Laere, K. V., & Vandenberghe, W. (2020) · Movement Disorders · doi:10.1002/mds.28216 · Cited by 110
“SV2A is strongly concentrated in presynaptic boutons, is essentially undetectable in cell bodies, and is present in virtually all presynaptic terminals.(15,18) These characteristics make SV2A an excellent marker to compare changes in density of presynaptic terminals between different brain regions.”
BackgroundSim, J. H., & Song, C. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611466 · Cited by 98
Human Positron Emission Tomography Neuroimaging
Hooker, J. M., & Carson, R. E. (2019) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-062117-121056 · Cited by 105
Self-citationMolecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 100
Emerging pathways driving early synaptic pathology in Alzheimer's disease
Briggs, C. A., Chakroborty, S., & Stutzmann, G. E. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.088 · Cited by 101
“However, the recent identification of a PET ligand to measure synaptic density in human patients [44] is an exciting new tool, and stands to provide meaningful diagnostic and predictive information related to synapse loss in disease progression.”
BackgroundSynaptic Loss in Primary Tauopathies Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Holland, N., Jones, P. S., Savulich, G., Wiggins, J. K., Hong, Y. T., Fryer, T. D., Manavaki, R., Sephton, S. M., Boros, I., Malpetti, M., et al. (2020) · Movement Disorders · doi:10.1002/mds.28188 · Cited by 93
“We acknowledge the potential for off-target binding, but preclinical data indicate very high correlations between UCB-J and synaptophysin, a marker of presynaptic vesicular density.(25) Our diagnoses were clinical, without neuropathology, although the clinicopathological correlations of PSP-Richardson’s syndrome are v…”
ResultIs intracranial volume a suitable proxy for brain reserve?
van Loenhoud, A. C., Groot, C., Vogel, J. W., van der Flier, W. M., & Ossenkoppele, R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0408-5 · Cited by 101
“Also, possible candidates in future studies would include diffusion tensor imaging or indices of microstructural integrity of the brain, such as in-vivo examination of dendritic spine length, synaptic density, or synaptic proteins using synaptic vesicle tracers for positron emission tomography (PET) [10, 19].”
BackgroundVisualization of AMPA receptors in living human brain with positron emission tomography
Miyazaki, T., Nakajima, W., Hatano, M., Shibata, Y., Kuroki, Y., Arisawa, T., Serizawa, A., Sano, A., Kogami, S., Yamanoue, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0723-9 · Cited by 97
Boros, B. D., Greathouse, K. M., Gearing, M., & Herskowitz, J. H. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.003 · Cited by 90
“Currently, this analysis can only be conducted on postmortem samples; however recent advances in PET suggest the possibility of synaptic density measurements in living humans (Finnema et al., 2016).”
BackgroundIn vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment
Vanhaute, H., Ceccarini, J., Michiels, L., Koole, M., Sunaert, S., Lemmens, R., Triau, E., Emsell, L., Vandenbulcke, M., & Van Laere, K. (2020) · Neurology · doi:10.1212/wnl.0000000000009818 · Cited by 88
“(11)C-UCB-J targets synaptic vesicle glycoprotein 2A (SV2A), which is ubiquitously expressed in presynaptic terminals(9) and serves as a proxy for synaptic density.(10) A limited number of recent SV2A PET studies have demonstrated hippocampal synaptic loss in AD.”
BackgroundSala, A., & Perani, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00617 · Cited by 97
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 93
Mansur, A., Rabiner, E. A., Comley, R. A., Lewis, Y. L., Middleton, L. T., Huiban, M., Passchier, J., Tsukada, H., & Gunn, R. N. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.228080 · Cited by 87
“11C-UCB-J uptake was widespread and displayed fast kinetics that were well described by all 3 models, in agreement with previous reports (21).”
MethodResultReduced Synaptic Density in Patients with Lewy Body Dementia: An [ 11 C ] UCB‐J PET Imaging Study
Andersen, K. B., Hansen, A. K., Damholdt, M. F., Horsager, J., Skjærbæk, C., Gottrup, H., Klit, H., Schacht, A. C., Danielsen, E. H., Brooks, D. J., et al. (2021) · Movement Disorders · doi:10.1002/mds.28617 · Cited by 84
“The novel positron emission tomography (PET) tracer [(11)C]UCB-J has recently been developed as an in vivo imaging technique to quantify the density of presynaptic vesicle protein SV2A, which is ubiquitously present in all pre-synaptic terminals.(12) An excellent linear correlation between SV2A and the “gold standard”…”
BackgroundMethodInfluentialToyonaga, T., Smith, L. M., Finnema, S. J., Gallezot, J.-D., Naganawa, M., Bini, J., Mulnix, T., Cai, Z., Ropchan, J., Huang, Y., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223867 · Cited by 79
“We showed that 11C-UCB-J PET intensity correlates well with in vitro histopathologic synaptic markers and allows an evaluation of synaptic density in vivo (2).”
BackgroundSelf-citationImaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
“All PET imaging and measurement of the metabolite-corrected arterial input function was performed according to previously described procedures [41, 49], and outlined in Supplementary Methods.”
MethodSelf-citationSynaptic dysfunction and altered excitability in C9ORF72 ALS/FTD
Starr, A., & Sattler, R. (2018) · Brain Research · doi:10.1016/j.brainres.2018.02.011 · Cited by 78
Finnema, S. J., Toyonaga, T., Detyniecki, K., Chen, M., Dias, M., Wang, Q., Lin, S., Naganawa, M., Gallezot, J., Lu, Y., et al. (2020) · Epilepsia · doi:10.1111/epi.16653 · Cited by 78
Self-citationSynaptic vesicle protein 2A as a potential biomarker in synaptopathies
Heurling, K., Ashton, N. J., Leuzy, A., Zimmer, E. R., Blennow, K., Zetterberg, H., Eriksson, J., Lubberink, M., & Schöll, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.02.001 · Cited by 77
Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond
Koola, M. M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113409 · Cited by 84
Neurophysiological signatures of cortical micro-architecture
Shafiei, G., Fulcher, B., Voytek, B., Satterthwaite, T. D., Baillet, S., & Mišić, B. (2023) · Nature Communications · doi:10.1038/s41467-023-41689-6 · Cited by 87
Constantinescu, C. C., Tresse, C., Zheng, M., Gouasmat, A., Carroll, V. M., Mistico, L., Alagille, D., Sandiego, C. M., Papin, C., MAREK, K. L., et al. (2018) · Molecular Imaging and Biology · doi:10.1007/s11307-018-1260-5 · Cited by 77
Positron emission tomography in multiple sclerosis - straight to the target
Bodini, B., Tonietto, M., Airas, L., & Stankoff, B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00537-1 · Cited by 74
Nakamura, T., & Takata, A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02005-2 · Cited by 74
“…recent technological advances have allowed us to quantify some key molecules involved in the regulation of synapses and histone modi fi cations, such as the synaptic vesicle glycoprotein 2A [127], AMPA-type glutamate receptors [128], and histone deace-tylases (HDACs) [129] in the living human brain.”
BackgroundImaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67
“Nevertheless, it was not until 2016 that the full potential of these radiotracers was unveiled: the possibility to detect changes in synaptic density in vivo (Finnema et al., 2016; Morris, 2016; Mercier et al., 2017) through regional quantification of brain SV2A expression.”
BackgroundRibarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Tau and atrophy: domain-specific relationships with cognition
Initiative, A. D. N., Digma, L. A., Madsen, J. R., Reas, E. T., Dale, A. M., Brewer, J. B., & Banks, S. J. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0518-8 · Cited by 70
“Some of these alterations, which can now be estimated in vivo using PET [55], should be the focus of future studies to provide a better view of how the hallmark AD pathologies like tau drive decline and to realize new potential avenues for therapeutic intervention.”
BackgroundSustained effects of single doses of classical psychedelics in humans
Knudsen, G. M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01361-x · Cited by 78
“More recently, it has become possible to conduct PET imaging of the synaptic vesicular protein 2A (SV2A) in vivo in humans and there is some evidence to support that SV2A is an alternative synaptic density marker to synaptophysin [45].”
BackgroundThomsen, M. B., Ferreira, S. A., Schacht, A. C., Jacobsen, J., Simonsen, M., Betzer, C., Jensen, P. H., Brooks, D. J., Landau, A. M., & Romero‐Ramos, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105229 · Cited by 68
Finnema, S. J., Rossano, S., Naganawa, M., Henry, S., Gao, H., Pracitto, R., Maguire, R. P., Mercier, J., Kervyn, S., Nicolas, J., et al. (2019) · Epilepsia · doi:10.1111/epi.14701 · Cited by 65
Self-citationImpairments of glutamatergic synaptic transmission in Alzheimer’s disease
Zott, B., & Konnerth, A. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.03.013 · Cited by 70
Carter, S. F., Chiotis, K., Nordberg, A. K., & Rodriguez‐Vieitez, E. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4217-7 · Cited by 67
Agnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Hashemi, P., Carhart-Harris, R. L., Nutt, D., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 67
“Despite the pharmacological diversity within classic psy-chedelics, agonism of the 5-HT receptor type 2 A (5-HT2AR) appears to be the primary mechanism via which these drugs ’ subjective effects are mediated (Nichols, 2016).”
Li, S., Naganawa, M., Pracitto, R., Najafzadeh, S., Holden, D., Henry, S., Matuskey, D., Emery, P. R., Cai, Z., Ropchan, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05149-3 · Cited by 61
“The decreased binding corresponded well with previous tissue analysis, and the binding asymmetry was more specifically localized to the seizure onset zone (SOZ), while the change in [(18)F]FDG uptake also extended to the adjacent regions [14].”
BackgroundSelf-citationMeasuring brain synaptic vesicle protein 2A with positron emission tomography and [ 18 F]UCB‐H
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61
“SV2A is a suitable marker of synaptic density, and we discuss its brain distribution and modeling properties compared to the recently published SV2A tracer [(11)C]UCB-J [14].”
BackgroundMethodResultSelf-citationMertens, N., Maguire, R. P., Serdons, K., Lacroix, B. D., Mercier, J., Sciberras, D. G., Laere, K. V., & Koole, M. J. B. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01387-6 · Cited by 60
Self-citationSynaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study
Michiels, L., Delva, A., van Aalst, J., Ceccarini, J., Vandenberghe, W., Vandenbulcke, M., Koole, M., Lemmens, R., & Laere, K. V. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117877 · Cited by 59
Li, S., Cai, Z., Zhang, W., Holden, D., Lin, S.-F., Finnema, S. J., Shirali, A., Ropchan, J., Carre, S., Mercier, J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04357-w · Cited by 59
Self-citationNerella, S. G., Bhattacharya, A., Joshi, R. K., Nagaraj, C., Bharath, R. D., & Kumar, P. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01053 · Cited by 60
The 22q11.2 region regulates presynaptic gene-products linked to schizophrenia
Nehme, R., Pietiläinen, O., Artomov, M., Tegtmeyer, M., Valakh, V., Lehtonen, L., Bell, C., Singh, T., Trehan, A., Sherwood, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31436-8 · Cited by 58
Volpi, T., Maccioni, L., Colpo, M., Debiasi, G., Capotosti, A., Ciceri, T., Carson, R. E., DeLorenzo, C., Hahn, A., Knudsen, G. M., et al. (2023) · EJNMMI Research · doi:10.1186/s13550-023-01050-w · Cited by 60
“These parameters are useful for many applications, such as the measurement of drug occupancy, or the assessment of new radioligands [2].”
BackgroundSelf-citationQuantitative positron emission tomography in brain research
Heurling, K., Leuzy, A., Jonasson, M., Frick, A., Zimmer, E. R., Nordberg, A. K., & Lubberink, M. (2017) · Brain Research · doi:10.1016/j.brainres.2017.06.022 · Cited by 63
Synaptic vesicle protein 2: A multi-faceted regulator of secretion
Ciruelas, K., Marcotulli, D., & Bajjalieh, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.02.003 · Cited by 64
Metadata
- Authors
- Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, D. D., Mercier, J., Hannestad, J., Huang, Y., & Carson, R. E.
- Affiliations
- Yale University (US)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Finnema, Sjoerd J.
- Hannestad, Jonas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-07-20
- Volume
- 8
- Issue
- 348
- Pages
- 348ra96-348ra96
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2503767557
- Cited by
- 575
- References
- 59
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 81 · 2023: 54 · 2022: 92 · 2021: 67 · 2020: 54 · 2019: 43 · 2018: 23 · 2017: 31 · 2016: 6
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Swebilius Foundation
- UCB Pharma
- Swedish Research Council
- National Center for Advancing Translational Science (UL1 TR000142)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- synaptic density, SV2A, positron emission tomography, presynaptic terminals, synaptophysin, temporal lobe epilepsy, synaptic loss, Alzheimer's disease, neuroimaging
- MeSH terms
- Adult, Aged, Brain, Epilepsy, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Synapses, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.